NASDAQ:TXMD - TherapeuticsMD Stock Price, Forecast & News

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

TherapeuticsMD Inc (NASDAQ:TXMD) announced its quarterly earnings data on Wednesday, November, 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.19) by $0.06. The business earned $8.21 million during the quarter, compared to the consensus estimate of $8.05 million. TherapeuticsMD had a negative net margin of 427.70% and a negative return on equity of 430.28%. The firm's quarterly revenue was up 136.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.16) earnings per share. View TherapeuticsMD's Earnings History.

TherapeuticsMD is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for TherapeuticsMD.

9 equities research analysts have issued 12 month target prices for TherapeuticsMD's shares. Their forecasts range from $3.00 to $17.00. On average, they expect TherapeuticsMD's stock price to reach $9.11 in the next year. This suggests a possible upside of 273.4% from the stock's current price. View Analyst Price Targets for TherapeuticsMD.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TherapeuticsMD.

Media headlines about TXMD stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. TherapeuticsMD earned a coverage optimism score of -1.4 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for TherapeuticsMD.

TherapeuticsMD saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 86,820,000 shares, an increase of 9.4% from the December 31st total of 79,360,000 shares. Based on an average daily volume of 3,670,000 shares, the short-interest ratio is currently 23.7 days. Currently, 36.6% of the shares of the stock are sold short. View TherapeuticsMD's Current Options Chain.

Some companies that are related to TherapeuticsMD include ArQule (ARQL), ChemoCentryx (CCXI), Karuna Therapeutics (KRTX), Zogenix (ZGNX), Amicus Therapeutics (FOLD), Ra Pharmaceuticals (RARX), Synthorx (THOR), Arena Pharmaceuticals (ARNA), Aurinia Pharmaceuticals (AUPH), Turning Point Therapeutics (TPTX), Prestige Consumer Healthcare (PBH), Aimmune Therapeutics (AIMT), Epizyme (EPZM), Heron Therapeutics (HRTX) and Eidos Therapeutics (EIDX).

Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include Opko Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Cleveland-Cliffs (CLF), CannTrust (CNTTF), NVIDIA (NVDA), Horizon Therapeutics (HZNP), bluebird bio (BLUE), Global Blood Therapeutics (GBT) and Novavax (NVAX).

TherapeuticsMD's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Sanders Morris Harris LLC (0.14%) and Janney Montgomery Scott LLC (0.05%). Company insiders that own TherapeuticsMD stock include Angus C Russell, Brian Bernick, Daniel A Cartwright, Group L P Column, Jane F Barlow, John CK Iv Milligan, Jules A Musing, Robert G Finizio and Tommy G Thompson. View Institutional Ownership Trends for TherapeuticsMD.

TXMD stock was sold by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC. View Insider Buying and Selling for TherapeuticsMD.

TXMD stock was bought by a variety of institutional investors in the last quarter, including Janney Montgomery Scott LLC. Company insiders that have bought TherapeuticsMD stock in the last two years include Angus C Russell, Brian Bernick, Group L P Column, Jane F Barlow, John CK Iv Milligan, Robert G Finizio and Tommy G Thompson. View Insider Buying and Selling for TherapeuticsMD.

Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TXMD stock can currently be purchased for approximately $2.44.

TherapeuticsMD has a market capitalization of $661.68 million and generates $16.10 million in revenue each year. The company earns $-132,620,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. TherapeuticsMD employs 241 workers across the globe.View Additional Information About TherapeuticsMD.

The official website for TherapeuticsMD is http://www.therapeuticsmd.com/.

TherapeuticsMD's mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. The company can be reached via phone at 561-961-1900 or via email at [email protected]